



LKT Laboratories, Inc.

R-Bicalutamide

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: sales@lktlabs.com

Product Information

Product ID B3210

CAS No. 113299-40-4

Chemical Name R-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methyl-, (+/-)- Propanamide

Synonym


Formula C18H14F4N2O4S

Formula Wt. 430.37

Melting Point 178-179°C

Purity ≥98%

Solubility water: 5mg/L



Product ID	Size
B3210	25 mg
B3210	100 mg
B3210	250 mg
B3210	1 g

Store Temp Ambient

Ship Temp Ambient

Description R-Bicalutimide is an inhibitor of the androgen receptor that exhibits anticancer chemotherapeutic activity. With other anti-androgens, R-bicalutimide decreases levels of Bcl-2, Bcl-XL, caspase-3, and PARP, induces apoptosis, and inhibits cell growth of prostate cancer cells. In similar animal models, this compound decreases plasma PSA levels and suppresses tumor growth. Bicalutamide binds the androgen receptor in two sites, distorting coactivator binding and inhibiting transcription.

Optical rotation: $[\alpha]_{20}^D = -83.0 - 85.0$ (C=1, MeOH)

References Squillace RM, Miller D, Wardwell SD, et al. Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. *Int J Oncol.* 2012 Aug;41(2):425-32. PMID: 22614157.

Yan J, Xie B, Capodice JL, et al. Zylamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth. *Prostate.* 2012 Feb;72(3):244-52. PMID: 21656835.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.